Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide for induction of remission in incomplete microscopic colitis
NL-OMON45182Phase 3Active, not recruiting
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- Dec 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in microscopic colitis (MC) comparing Budesonide with Placebo (2 arms). Primary endpoint: Rate of clinical remission at final or withdrawal visit. Started Dec 2015; status: active, not recruiting.
02
Drugs
budesonide
03
Conditions
microscopic colitis (MC)
Beyond the preview
Go deeper on NL-OMON45182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45182.